Sangamo Therapeutics, Inc.

NasdaqGS:SGMO Rapporto sulle azioni

Cap. di mercato: US$180.5m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sangamo Therapeutics Dividendo

Dividendo criteri di controllo 0/6

Sangamo Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore1.9%
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Utile per azione-US$1.20
Previsione del rendimento del dividendo0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Aug 03
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Jul 23

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

Jun 19
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

May 14
This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Mar 23
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Mar 16
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Mar 09
We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Feb 02
Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Dec 04
Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Sep 11
Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Aug 15
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Aug 08
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

May 30
Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

May 13
Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Apr 11
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Dec 20
We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy

Sep 22

Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sep 18
Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead

Aug 31

Sangamo Therapeutics: Cheap, But Justifiably So

Aug 09

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

May 08
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Apr 11
Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Sangamo Therapeutics: Lost In Transition From Lab To Clinic

Feb 24

Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?

Jan 10
Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?

Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December

Dec 03

We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow

Sep 22
We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow

Sangamo Therapeutics: Finding An Opportunity To Reload

Aug 21

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di SGMO siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di SGMO siano aumentati.


Rendimento dei dividendi rispetto al mercato

Sangamo Therapeutics Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di SGMO rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (SGMO)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.3%
Media del settore (Biotechs)1.9%
Analista previsionale (SGMO) (fino a 3 anni)0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di SGMO rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di SGMO rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.


Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di SGMO per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.


Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché SGMO non ha segnalato alcun pagamento.


Scoprire le società che pagano dividendi forti